Related Articles for PubMed (Select 18366658)

The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.

Fassett RG, Ball MJ, Robertson IK, Geraghty DP, Coombes JS.

BMC Nephrol. 2008 Mar 18;9:4.

PMID: 18366658 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant]

Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C.

Presse Med. 2006 Feb;35(2 Pt 1):219-29. Review. French.

PMID: 16493350 [PubMed - indexed for MEDLINE]

Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.

Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK; Treating to New Targets Steering Committee and Investigators.

Mayo Clin Proc. 2008 Aug;83(8):870-9.

PMID: 18674471 [PubMed - indexed for MEDLINE]

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators.

JAMA. 2004 Mar 3;291(9):1071-80.

PMID: 14996776 [PubMed - indexed for MEDLINE]

Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial.

Summers MJ, Oliver KR, Coombes JS, Fassett RG.

Pharmacotherapy. 2007 Feb;27(2):183-90.

PMID: 17253908 [PubMed - indexed for MEDLINE]

Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.

van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R.

J Nephrol. 2003 Mar-Apr;16(2):238-44.

PMID: 12768071 [PubMed - indexed for MEDLINE]

Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.

Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR.

J Clin Endocrinol Metab. 2007 Dec;92(12):4671-7. Epub 2007 Aug 28.

PMID: 17726081 [PubMed - indexed for MEDLINE]

Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial.

Schmermund A, Achenbach S, Budde T, Buziashvili Y, Förster A, Friedrich G, Henein M, Kerkhoff G, Knollmann F, Kukharchuk V, Lahiri A, Leischik R, Moshage W, Schartl M, Siffert W, Steinhagen-Thiessen E, Sinitsyn V, Vogt A, Wiedeking B, Erbel R.

Circulation. 2006 Jan 24;113(3):427-37. Epub 2006 Jan 16.

PMID: 16415377 [PubMed - indexed for MEDLINE]

Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial.

Shukla A, Sharma MK, Jain A, Goel PK.

Indian Heart J. 2005 Nov-Dec;57(6):675-80.

PMID: 16521637 [PubMed - indexed for MEDLINE]

10:

Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study.

Nanayakkara PW, van Guldener C, ter Wee PM, Scheffer PG, van Ittersum FJ, Twisk JW, Teerlink T, van Dorp W, Stehouwer CD.

Arch Intern Med. 2007 Jun 25;167(12):1262-70.

PMID: 17592099 [PubMed - indexed for MEDLINE]

11: